Mizuho stays Outperform rated on Eikon Therapeutics Inc. (EIKN) following FY25 earnings and pipeline update
Tweet Send to a Friend
Mizuho analyst Joseph Catanzaro reiterated an Outperform rating and $26.00 price target on Eikon Therapeutics Inc. (NASDAQ: EIKN)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
